Kornimate/medical-research-clean huggingface dataset:
analysis of inflammation in the vitiligo and other inflammatory skin diseases: psoriasis, atopic dermatitis and alopecia areata

Conditions: Vitiligo; Psoriasis; Alopecia Areata; Atopic Dermatitis

Summary: it is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders

this study was a single-center prospective study to collect blood and skin tissue at the time of consultation with a patient with non-segmental vitiligo, psoriasis, atopic dermatitis or alopecia areata, in order to better understand and compare blood and skin immune response in chronic inflammatory skin disorders: psoriasis, alopecia areata, atopic dermatitis and vitiligo.

Eligibility criteria:
inclusion criteria: * patients aged 18 to 75 years; * patients with non-segmental vitiligo; * patients with plaque psoriasis; * patients with atopic dermatitis; * patients with alopecia areata sclerosis; * written consent, free, informed and signed by the patient and the investigator (before any examination required by the study); * subject affiliated or beneficiary of a social security system. exclusion criteria: * patients with segmental vitiligo * patients under local treatment (topical corticosteroid-calcineurin inhibitor) for less than two weeks. * patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine, apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, dupilumab) for less than 4 weeks. * pregnant or breastfeeding women * patient (e) under guardianship * patient (e) non-affiliated (e) a social protection

Keywords: skin inflammation cytokines
outcomes from an asthma disease management program

Conditions: Asthma

Summary: disease management is used to manage patients who have asthma and who are enrolled in a managed care health plan. to understand the effect of disease management on asthma severity and utilization, the investigators at children's mercy hospitals and clinics, will review data from a medicaid health maintenance organization (hmo) to determine the number of health plan members with different asthma severities and what their outcomes are. this will help us to improve the service provided to these patients. the investigators wish to publish this so that other health plans can benefit from the investigators experience.

disease management is used to manage patients who have asthma and who are enrolled in a managed care health plan. to understand the effect of disease management on asthma severity and utilization, we will review data from a medicaid hmo to determine the number of health plan members with different asthma severities and what their outcomes are. this will help us to improve the service provided to these patients. data on subjects already exists in the health management database. we will use data that has been collected between january 1, 2000 and august 18, 2005. we will use a convenience sample consisting of available subjects meeting the program criteria. the total fhp database includes approximately 50,000 members from which approximately 6,000 have been identified as having asthma. we will create a research database that will not contain any patient-specific data. instead, an intermediate workstation will be programmed to query the health management database and send the resulting aggregated and de-identified data to the research database for analysis on another workstation. the research database will never contain any patient identifiers nor will it contain individual patient data. it only will contain aggregated data provided by the intermediate query workstation. here is a complete list of variables that will be housed in the research database for subsequent analysis: categorical variables: asthma severity (intermittent, mild, moderate or severe persistent), provider office, quarter when seen, medication type (controller or reliever), age category (0-4, 5-9, 10-17, \>17years), active status (active or inactive), location (er, inpatient, routine visit), case managed (yes, no), gender, psychosocial issues, diagnosis (asthma, not asthma) continuous variables: cost of care, number of visits, number of prescriptions, number of members in the above categories, mean quality of life

Eligibility criteria:
inclusion criteria: * health plan members who have undergone disease management and who have a diagnosis of asthma (icd9 code of 493.xx)

Keywords: asthma disease management outcomes utilization
a multicenter study of the pigmentation in the trabecular meshwork after two years of treatment with travatan 0.004% ophthalmic solution

Conditions: Open-angle Glaucoma

Summary: the purpose of this study was to assess the pigmentation in the trabecular meshwork of patients who had been treated for at least 2 years with travatan compared with patients without exposure (or less than 1 month) to a prostaglandin analogue (pga).


Eligibility criteria:
inclusion criteria: * diagnosis of open-angle glaucoma without pseudoexfoliation or pigment dispersion component; * either two or more years of dosing with travatan, or no prior exposure (less than 1 month) to a topical ocular prostaglandin; * requires a trabeculectomy; * other protocol-defined inclusion criteria may apply. exclusion criteria: * pseudoexfoliation or pigment dispersion; * history of chronic or recurrent severe inflammatory eye disease; * history of or current ocular infection or ocular inflammation within the past 3 months in either eye; * greater than one month but less than two years of exposure to travatan; * pregnant, breast-feeding, not using highly effective birth control; * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma travatan trabeculectomy
improved patient safety for acute restless medical patients with supplemental observation

Conditions: Delirium

Summary: the aim of the study is to investigate whether supplemental camera observation directly linked to the nurse's phone will improve patient safety for acute medical care patients', who are restless, confused or in risk of development of acute delirium. the setting is an acute medical care ward. the expected result is a reduced incidence of patients with delirious condition, patients who fall or unintentionally remove intravenous access or catheters. thus, higher patient safety and more efficient patient trajectories are expected, as well as a reduced need for treatment, care and rehabilitation after discharge.


Eligibility criteria:
inclusion criteria: * patients over 65 years of age with a cam score of 2 or higher. exclusion criteria: * paranoia * severe dementia * suicidal * need for permanent guard
clearance of nasal staphylococcus aureus with triple antibiotic ointment

Conditions: Nasal Carriers of Staphylococcus Aureus

Summary: staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. this research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.


Eligibility criteria:
inclusion criteria: * willing and able to give informed consent * must have consented prior to registration for the study exclusion criteria: * active infection * concurrent treatment with antibiotics, topical or systemic * s. aureus decolonization attempt in prior six months * history of hiv * chemotherapy or systemic immunosuppressive therapy * history of neomycin allergy or sensitivity

Keywords: healthcare staphylococcus aureus nasal
study to evaluate safety and efficacy of filgotinib and lanraplenib in females with moderately-to-severely active cutaneous lupus erythematosus (cle)

Conditions: Cutaneous Lupus Erythematosus

Summary: the primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly gs-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (cle).


Eligibility criteria:
key inclusion criteria: * must have a diagnosis of cle, either chronic (e.g., discoid) or subacute cle per investigator evaluation, with the following: * moderately-to-severely active cle (cutaneous lupus erythematosus disease area and severity index \[clasi\] activity score ≥ 10) at screening and day 1 * prior intolerance or inadequate response to at least one of the listed medications for the treatment of cle * stable dose (defined as no change in prescription for at least 28 days prior to day 1) of antimalarials and/or topical or oral corticosteroids is permitted during the study. individuals who are not planning to continue these medications during the study must have discontinued them at least 28 days prior to day 1 key exclusion criteria: * use of prohibited concomitant medications per study protocol note: other protocol defined inclusion/exclusion criteria may apply.
reduced intensity conditioning using cd3+/cd19+ depletion for non malignant transplantable diseases

Conditions: Bone Marrow Failure Syndromes; Immunodeficiencies; Immune Dysregulation Syndromes

Summary: this is a phase ii trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with cd3+ /cd19+ depleted peripheral stem cell grafts from mismatched donors. there are two conditioning regimens depending upon patient diagnosis and age.

this study will allow transplantation using a reduced intensity conditioning regimen for children with non-malignant diseases who lack a matched related or unrelated donor. donors will be unrelated or partially matched related, depending upon urgency and availability. if each parent is haploidentical, the mother will be preferred, as there is evidence of reduced transplant related mortality and superior survival with a maternal donor. the risks of severe graft vs host disease (gvhd) and epstein-barr lymphoproliferative disorder will be reduced or eliminated by t and b cell depletion using the miltenyi clinimacs device. patients with bone marrow failure syndromes, who are at high risk for rejection, will undergo pre-conditioning immune suppression with thymoglobulin. it is recommended that patients with immunedysregulation syndromes receive pre-ric alemtuzumab as this may reduce the risk on non-engraftment and hyperinflammatory states. post-transplant immune suppression will be used to prevent gvhd, as cd3 depletion does not deplete as completely as cd34+ selection. it will be rapidly weaned if no gvhd by day 100 to allow immune reconstitution.

Eligibility criteria:
inclusion criteria: * bone marrow failure syndromes for which sct is indicated, including severe aplastic anemia refractory to non transplant therapies congenital neutropenia, congenital thrombocytopenia, congenital red cell aplasia * immunodeficiencies for which allogeneic hematopoietic stem cell transplant is indicated, including severe combined immunodeficiencies, wiskott-aldrich syndrome, ipex syndrome, x-linked lymphoproliferative disease * immune dysregulation syndromes, including refractory or recurrent hemophagocytic lymphohistiocytosis, hlh with genetic mutations, refractory multisystemic langerhans cell histiocytosis, other mas refractory to standard therapy * organ function clearance exclusion criteria: * uncontrolled bacterial, viral or fungal infections * hla matched related or unrelated donor able to donate mobilized peripheral stem cells. * fanconi's syndrome, dyskeratosis congenita or other chromosomal fragility syndromes * pregnant females

Keywords: transplant related mortality graft versus host disease bone marrow transplant
antibiotics for delirium in older adults with no clear urinary tract infection

Conditions: Infectious Disease

Summary: delirium is an acute confusional state that is experienced by many older adults who are admitted to hospital. to treat delirium the underlying cause needs to be identified promptly, but this is challenging. one of the potential causes of delirium is infection. urine tests show that most patients experiencing delirium have bacteria in their urine, however, bacteria in the urine is common among older adults, and does not automatically indicate an infection is present. as a result it is difficult to know whether a lower urinary tract infection is present as individuals with delirium are frequently unable to report clinical signs of infection - symptoms of pain or discomfort with urination, having to urinate more frequently or pelvic discomfort. very often, individuals with delirium are treated with antibiotics despite the fact that it is unknown whether antibiotics help to improve delirium in cases where bacteria in the urine is present. this proposed study is a randomized controlled trial that will examine if adults (age 60 or older) with delirium and suspected infection benefit from taking antibiotics.


Eligibility criteria:
inclusion criteria * age ≥ 60 and admitted to a hospital ward (including rehabilitation hospital); * active delirium (defined by cam: \[1\] inattention and \[2\] acute and fluctuating level of consciousness, and either \[3\] disorganized thinking or \[4\] altered mental status; or physician's diagnosis) * less than 24 hours of antibiotics (prior to trial assessment) * either pyuria (defined as white blood cells detected on urinalysis or dipstick) or bacteriuria (defined as bacteria growing on urine culture) exclusion criteria * fever (temperature \> 37.9c or \> 100.2f) in the past 48 hours; * signs of lower urinary tract infection symptoms (such as new dysuria) or upper urinary symptoms (such as costovertebral tenderness) * in the opinion of the treating physician, there is a reason apart from delirium and urine test results to treat with antibiotics (e.g., pneumonia) * indwelling urinary catheter for \> 72 hours * receipt of an antibiotic where a single dose suffices for the treatment of a uti (such as fosfomycin)

Keywords: delirium antibiotics older adults urinary tract infection
imaging in the diagnosis of parkinson's disease and essential tremor

Conditions: Parkinson's Disease; Essential Tremor

Summary: parkinson´s disease (pd) diagnosis is based upon clinical examination. although imaging has helped doctors to identify many diseases, it still does not add too much information for the diagnosis of parkinson´s disease. the investigators are going to perform a large sample study including pd patients, essential tremor and healthy volunteers in order to evaluate if mri can help in the diagnosis. our hypothesis is that fractional anisotropy (fa) in the caudal portion of substantia nigra is decreased in pd patients.

the diagnosis of parkinson's disease (pd) is based on a set of clinical assessments that do not provide great accuracy. although magnetic resonance imaging (mri) and transcranial sonography (tcs) have provided important advances in the diagnosis of a number of neurological diseases, few biomarkers of pd have been described in order to support its clinical diagnosis. recently, one single study showed that high field mri using diffusion tensor imaging (dti) was able discriminate pd from healthy volunteers. this study had a small sample size (14 patients and 14 controls) and did not include the main differential diagnosis of pd. the main objective of this study is to confirm previous findings, with a larger sample size, describe possible changes of dti parameters in patients with essential tremor (one of the main differential diagnosis of pd), and compare dti mri with tcs. our primary outcome will be the fractional anisotropy (fa) in the caudal portion of substantia nigra. as a consequence, new algorithm to discriminate pd, essential tremor and healthy volunteers will be proposed. this has a pivotal importance in order to provide support to clinical diagnosis of pd and increase its accuracy.

Eligibility criteria:
inclusion criteria: * parkinson´s disease patients according to uk parkinson´s disease brain bank criteria * essential tremor patients according to movement disorder´s diagnosis consensus criteria. * healthy volunteers: paired with pd patients by age and gender. exclusion criteria: * contraindication to mri * claustrophobia. * serious structural brain anomalies. * condition or situation in which, in the opinion of the investigator put the patient at significant risk, which can confound the results, or substantially interfere with the individual's participation in the study.

Keywords: mri parkinson's disease essential tremor ultrasonography diagnosis
syphilis video tool to promote knowledge and testing in the ed

Conditions: Syphilis

Summary: the objective of this study is to determine whether the "syphilis and men" educational video can be a useful tool to increase syphilis knowledge and testing among english and spanish-speaking urgent care and emergency department patients, regardless of various self-reported characteristics that increase their risk for syphilis infection.

a randomized four-group intervention-control solomon design was implemented with group 1 participants receiving a pre-test survey, the educational video intervention, and a post-test survey; group 2 the pre-test and post-test surveys; group 3 the video intervention and a post-test survey; and group 4 the post-test survey. this design was selected to assess the effect of the video in increasing syphilis knowledge while controlling for the influence of the pre-test instrument in potentially sensitizing participants to key facts. a computer-generated randomization list was created and used to assign patients to groups.

Eligibility criteria:
inclusion criteria: * patients aged 18-55 years of age were eligible only if they spoke english or spanish. exclusion criteria: * patients were excluded if clinically unstable, unarousable, hearing impaired or visually impaired despite corrected lens.

Keywords: syphilis educational video knowledge black hispanic
a randomized comparison of personalized therapy mgmt based on coronary atherosclerotic plaque vs. usual care for symptomatic patients with suspicion of cad

Conditions: Coronary Artery Disease

Summary: paramount is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (cad), using a ct-based coronary atherosclerotic plaque assessment by ai-enabled quantitative software improves: certainty for diagnosis of cad, control of cad risk factors and efficiency of ica referral with appropriate pci compared to the usual care strategy based on current aha/acc guidelines for care of symptomatic patients with suspicion of cad.


Eligibility criteria:
inclusion criteria: * \> 18 years * symptomatic patients with suspicion of cad, including those referred for elective, non-urgent diagnostic testing (e.g. stress test) exclusion criteria: * ldl \< 100 mg/dl * currently or previously treated beyond primary prevention guidelines * suspected acute coronary syndrome or otherwise unstable clinical status * planned cardiovascular procedure (e.g. coronary angiography, cardiac surgery, non-coronary vascular procedure) * noninvasive or invasive cv testing for cad within 1 year (e.g. invasive coronary angiography (ica), coronary ct angiography (ccta) including calcium scoring) * known history of obstructive cad (prior myocardial infarction, cabg or pci, stenosis ≥50%) * known ef ≤40% or other moderate to severe valvular or congenital cardiac disease * contraindications to ccta
impact of positron emission tomography (pet) imaging in muscle-invasive urothelial carcinoma of the bladder staging

Conditions: Muscle-invasive Bladder Cancer

Summary: bladder cancer is the fifth most common cancer in canada and there has been relatively little progress in altering its clinical course over the last three decades. one of the major problems identified in the management of this disease, is under staging of muscle invasive disease which can lead to suboptimal treatment and outcomes. pet-ct has the potential to more accurately stage mibc than standard ct by detecting pelvic adenopathy and/or distant sites of disease that may not be found on standard imaging. in the former situation, more aggressive therapy with extended lymph node dissection and/or neoadjuvant chemotherapy prior to cystectomy can be offered. while in the latter situation patients can be spared the morbidity of a cystectomy performed in a setting of metastatic disease. this study will address whether pet-ct adds a clinically meaningful difference in care.

a multicenter randomized controlled trial will be performed. patients usually present with symptoms (e.g., painless hematuria). the urologist will perform cystoscopy and if urothelial cancer of the bladder is suspected, the patient is taken to the operating room for an examination under anesthesia (eua) and a turbt. if this shows muscle invasion then conventional staging with ct chest, abdomen, and pelvis is performed. the patient who has tnm stage t2a-t4a n0-3 m0 is eligible to be enrolled in the trial. eligible consenting patients will be randomized 2:1 to pet-ct or none (control). the actual treatment received by the patient will be documented. the primary outcome measure is treatment received.

Eligibility criteria:
inclusion criteria: * men and women with newly diagnosed muscle-invasive high grade urothelial carcinoma of the bladder (tnm stage t2a-t4a, n0-3, m0), who are eligible for either radical cystectomy or radiotherapy-based bladder conservation. * being considered for treatment of curative intent. exclusion criteria: * age \< 18 years. * ecog performance status \>2. * predominant histology (\>50% of specimen) involves non-urothelial cell carcinoma. * prior partial cystectomy. * prior pelvis surgery that obviates a completed extended lymphadenectomy (e.g., aorto-femoral/iliac bypass) or for whom the surgeon feels that their ability to perform a standard or extended pelvic node dissection would be compromised. * contraindications to fdg pet-ct. * inability to lie supine for imaging with pet-ct. * inadequate hepatic function: (i) bilirubin \>1.5 x uln and (ii) sgot and alkaline phosphatase \>3 x uln * history of another invasive malignancy within the previous 5 years with the exception of non-melanoma skin cancer. * known pregnancy or lactating female. * inability to complete the study or required follow-up.

Keywords: muscle-invasive bladder cancer bladder cancer pet imaging fdg
study to assess the incidence of intussusception in children < 2 years of age in singapore

Conditions: Intussusception

Summary: this prospective study aims to estimate the incidence of intussusception among children \< 2 years old through hospital-based surveillance in singapore.


Eligibility criteria:
inclusion criteria: * a male or female infant aged \< 24months at the time of diagnosis of intussusception. * subject is diagnosed with definite, probable, possible, suspected intussusception during the period of at least one year beginning at study start. * written informed consent obtained from the parent or guardian of the subject. exclusion criteria: * a male or female infant ≥ 24 months of age at the time of intussusception diagnosis. * the subject has had a radiographically or surgically confirmed case of intussusception prior to the current episode.